Man Group
TGTX icon

Man Group’s TG Therapeutics TGTX Stock Holding History

Man Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.27M Sell
132,376
-222,321
-63% -$9.1M 0.01% 945
2026
Q1 		$11.8M Sell
354,697
-601,940
-63% -$17.9M 0.02% 737
2025
Q4 		$28.5M Sell
956,637
-51,825
-5% -$1.69M 0.05% 376
2025
Q3 		$36.4M Buy
1,008,462
+868,697
+622% +$28.6M 0.06% 329
2025
Q2 		$5.03M Buy
+139,765
New +$5.2M 0.01% 1057
2025
Q1 		– Sell
-9,589
Closed -$289K – 2366
2024
Q4 		$289K Buy
+9,589
New +$275K ﹤0.01% 1803
2023
Q3 		– Sell
-689,236
Closed -$17.1M – 2144
2023
Q2 		$17.1M Buy
+689,236
New +$17.8M 0.05% 432
2023
Q1 		– Sell
-18,200
Closed -$215K – 2247
2022
Q4 		$215K Sell
18,200
-14,347
-44% -$104K ﹤0.01% 1745
2022
Q3 		$193K Buy
+32,547
New +$213K ﹤0.01% 1781
2022
Q2 		– Hold
0
– – – 1558
2021
Q4 		– Sell
-67,196
Closed -$2.24M – 2105
2021
Q3 		$2.24M Sell
67,196
-21,927
-25% -$678K 0.01% 1135
2021
Q2 		$3.46M Sell
89,123
-13,332
-13% -$524K 0.01% 1039
2021
Q1 		$4.94M Sell
102,455
-102,993
-50% -$4.95M 0.02% 698
2020
Q4 		$10.7M Sell
205,448
-4,636
-2% -$157K 0.05% 419
2020
Q3 		$5.62M Sell
210,084
-261,005
-55% -$6.01M 0.02% 750
2020
Q2 		$9.18M Buy
+471,089
New +$7.59M 0.05% 387
2019
Q4 		– Sell
-63,533
Closed -$357K – 1912
2019
Q3 		$357K Sell
63,533
-85,703
-57% -$597K ﹤0.01% 1636
2019
Q2 		$1.29M Sell
149,236
-40,500
-21% -$306K ﹤0.01% 1451
2019
Q1 		$1.52M Buy
+189,736
New +$1.03M 0.01% 1442
2018
Q3 		– Sell
-80,250
Closed -$1.05M – 2222
2018
Q2 		$1.05M Buy
+80,250
New +$1.1M ﹤0.01% 1592

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Man Group's TGTX Position: Q2 2026 in Review

Man Group reduced its TG Therapeutics (TGTX) stake by 63% in Q2 2026, selling an estimated $9.1M and leaving 132,376 shares worth $7.27M. The position accounts for 0.01% of the portfolio, ranked #945.

Man Group first reported a position in TGTX in Q2 2018 and has held it in 19 quarters since. The position peaked at $36.4M in Q3 2025. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Man Group held 132,376 shares of TG Therapeutics worth $7.27M as of Q2 2026.
  • Man Group sold 222,321 TG Therapeutics shares in Q2 2026, an estimated $9.1M.
  • TG Therapeutics made up 0.01% of Man Group's portfolio in Q2 2026, its #945 holding.
  • Man Group first reported a position in TG Therapeutics in Q2 2018 and has held it in 19 quarters since.
  • Man Group's TG Therapeutics position peaked at $36.4M in Q3 2025.
  • 428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.